Comparison of Solifenacin and Trospium in Treatment of Overactive Bladder
10.11969/j.issn.1673-548X.2017.11.035
- VernacularTitle:索利那新与曲司氯铵治疗膀胱过度活动症疗效与安全性的比较
- Author:
Wenjian LI
1
;
Xishan ZHU
;
Xiaonong DAI
Author Information
1. 213001,常州市第三人民医院
- Keywords:
Overactive bladder;
Solifenacin;
Trospium
- From:
Journal of Medical Research
2017;46(11):145-148
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the use of solifenacin and trospium in treatment of overactive bladder (OAB).Methods This prospective study was conducted on patients diagnosed with OAB who presenting to the Department of urology,Changzhou No.3 People's Hospital between March 2015 and May 2016.Patients were randomized into 2 groups.Group A (n =40) received 5 mg solifenacin once daily,while Group B (n =39) received 20 mg trospium twice daily.All the patients' OAB symptom scores (OABSS) in weeks 0,4,and 12 were recorded.In addition,side effects of the drugs were evaluated.Results Average OABSS was determined as:9.3 ± 2.6 (Group A) and 10.2±1.9 (Group B) at week0;2.5±1.3 (GroupA) and 2.7±1.4 (Group B) at week4;and 1.4±0.5 (Group A) and 1.3 ± 0.6 (Group B) at week 12.In addition,no statistically significant difference was found between the scores (P =0.084,P =0.512 and P =0.423).The discontinuation rate of medication due to its side effects was 0 (0％) for Group A,and 5 (12.8％) for Group B.Intragroup changes in the scores 0 weeks-4 weeks,0 weeks-12 weeks and 4 weeks-12 weeks values was statistically significant in both groups (P =0.000).Conclusion No significant difference was found between the OABSS of these 2 drugs.However,discontinuation of drugs due to side effects was more frequent in trospium.
